Google backs I/O startup Arcus in $107M deal

Arcus Biosciences, with a intriguing cancer tube and large shot CEO, has been a VC favorite given a pregnancy in 2015. Now, Google’s try arm is subsidy a Bay Area startup in a new $107 million round, bringing a company’s sum transport to a entertain billion in startup collateral in twin years.

The latest distillate of money was led by GV (formerly Google Ventures), with top-tier VC supports backing adult to join, including Wellington Management Company, EcoR1 Capital and others.

It’s not tough to see why, as Arcus has all a things investors like to see: drugs in a hot area of development, a arch executive with a stellar reputation, and a tube built with several immuno-oncology hopefuls.

Terry Rosen

Arcus’ CEO Terry Rosen is best famous as a man who took Flexus Bio from pregnancy to a $1.25 billion sale in reduction than twin years. He assimilated Arcus shortly after a sale, where he and a executive group built a startup in secrecy until a coming out party final August.

Now, Rosen is bustling gearing adult a startup’s tube to enter a clinic.

“We have been convention a group of staff, investors, care and advisors with a rarely aligned long-term prophesy to create, rise and commercialize innovative cancer immunotherapies that might offer a suggestive advantage to patients over existent treatments,” Rosen pronounced in a statement.

Arcus is building tiny proton and antibody programs with skeleton to build a possess arsenal of drug combos.

The new money will be used to pierce brazen AB928, a twin adenosine receptor antagonist, and AB122, a PD-1 antibody. Arcus started a Phase we hearing of AB928 in early November, and has a Phase I/II hearing scheduled for a initial half of 2018 to exam a AB928/AB122 combo in cancer patients.

The uninformed collateral will also concede Arcus to accelerate a integrate additional initial drugs into a clinic, including AB680 (small proton CD73 inhibitor) and AB154 (TIGIT antibody).

The investment turn comes a few months after Arcus scored a deal (worth adult to $816 million) to permit an anti-PD-1 antibody grown during China’s Gloria Pharma and WuXi Biologics.


Can we find your subsequent tube awaiting quickly? CancerLandscape™ can!

Quickly brand or review your tube contra competitors or intensity partners. Pinpoint ongoing trials by target, resource of action, drug or technology.

CancerLandscape™ built by oncology experts; corroborated by extensive and devoted information sources and leveraged by attention leaders.

More tabs ...

Posted in
Tagged . Bookmark the permalink.
short link